ep in-lin organ growth
organ growth vs cs estimate dollar basi
sale bil driven strength uro/pelv peripher
endoscopi off-set weaker rhythm neuromod
ep estim street sale net cog flat
lower non-op lower tax partial off-set lower sg
oper margin roughli line
guidanc also reiter ep guidanc
compar estim includ accret btg
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
boston scientif corp global manufactur provid
medic devic equip area vascular intervent
structur heart men women health
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
sale
sale
estimate
ep
sale
sale
estimate
charl martineau pm univers toronto compani mention price
